| Chen YK |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=1.604 ------>paper_class3=2 ------>paper_class2=1 ------>vol=25 ------>confirm_bywho=hychiou ------>insert_bywho=baich ------>Jurnal_Rank=73.2 ------>authors4_c= ------>comm_author= ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=4725 ------>medlineContent= ------>unit=J0200 ------>insert_date=20080312 ------>iam=4 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=500 ------>journal_name=Anticancer Research ------>paper_name=Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence ------>confirm_date=20080313 ------>tch_id=094128 ------>pmid=16334166 ------>page1=4719 ------>fullAbstract=The aim of this study was to evaluate the potential role of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with unexplained rising serum alpha-fetoprotein (AFP) levels after the treatment of hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Thirty-one FDG-PET studies were performed in 26 patients (age range, 45-83; 21 men and 5 women), who had undergone either surgical resection or interventional therapy for HCC, but were subsequently noted to have high AFP serum levels on routine follow-up examinations, although imaging studies and physical examinations were normal. The FDG-PET results were correlated with histological findings, as well as long-term radiological and clinical follow-up (shortest follow-up period after FDG-PET was 6 months). RESULTS: FDG-PET was abnormal in 22 of the 31 studies (71.0%) among the 26 patients. Intrahepatic lesions were detected in 20 of a total 30 lesions (66.7%) in 18 studies of FDG-PET among 26 patients. Ten FDG-PET studies among 9 patients identified one intrahepatic lesion, while 3 studies among 3 patients identified more than one intrahepatic lesion. Extrahepatic metastases were found in 9/31 studies of FDG-PET (29.0%) among 8 patients. These metastatic foci, composed of increased FDG accumulation, were identified in several locations; lung (4 studies among 4 patients), bone (2 studies among 2 patients) and the peritoneum (4 studies among 3 patients). Overall, FDG-PET for detecting HCC recurrence demonstrated 22 true-positives, 8 false-negatives, 1 true-negative and 0 false-positive results., The sensitivity, specificity and accuracy of FDG-PET for detecting HCC recurrence was 73.3%, 100% and 74.2%, respectively. CONCLUSION: When conventional examinations are normal, FDG-PET is a valuable imaging tool in patients who have rising AFP levels after HCC treatment. FDG-PET whole-body scan also provides an important and valuable imaging study for detecting extrahepatic metastasis. ------>tmu_sno=None ------>sno=16702 ------>authors2=Hsieh DS ------>authors3=Liao CS ------>authors4=Bai CH ------>authors5=Su CT ------>authors6=Shen YY, Hsieh JF, Liao AC, Kao CH ------>authors6_c= ------>authors=Chen YK ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no=6C ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2005 ------>submit_flag=None ------>publish_month=11 |